《大行》中金升信達生物(01801.HK)目標價至95.3元 CVM重磅管線接力兌現
中金表示,信達生物(01801.HK)公告心血管和代謝(CVM)領域重磅產品信爾美(瑪仕度(月太)注射液)作為全球首個GCG/GLP-1雙受體激動減重藥物在國內獲批上市。6月30日,公司舉辦腫瘤創新研發日活動,展示公司在下一代免疫治療(IO)與下一代抗體偶聯藥物(ADC)的戰略,並分享包括IBI363(PD-1/IL-2)在內的臨床進展和數據解讀。
中金認為公司CVM領域今年以來大單品替妥尤單抗、瑪仕度(月太)已經先後兌現,匹康奇拜也有望年內獲批上市,早期管線IBI3030等也均有看點;IO領域IBI363有望成為下一代IO重磅單品,ADC平台不斷收穫。中金認為公司自「後PD-1時代」轉型順利,CVM+IO領域管線豐富,有潛力解鎖其全球創新價值。
該行基本維持信達生物2025年及2026年歸母淨利潤預測4.72億元/12.99億元不變。考慮到瑪仕度(月太)獲批上市,創新管線國際化推進,基於現金流量折現法(DCF)模型,上調目標價38.1%至95.3港元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.